steady T, Investor, Biostockclub, others....great work. Thanks for your insights and assessments. It all helps the process of learning. Isn't it great to have the this kind of data. The Amyloid Thesis guys were not so generous. The PM process and the open work culture will continue to enable open team thinking and interaction. The output will be greater than the sum of the parts.
I am hopeful that the analysts at the big investment houses will do similar work and that they will recommend continued growth for AVXL. Expect some of that to show this coming week in sp growth. If the Amyloid thesis work is being put aside then resources in BP may look seriously at A2-73 and other AVXL CNS disease possibilities. Someone has to tell then that it is OK to want AVXL to win. If Dr.G. and the FDA brain-trust are half as smart as we think they are they will at least comment on these CTAD results positively.
Yes, more trials must be run and more discoveries will occur in the process but at least now it is a matter on WHEN, NOT IF CNS diseases will be treatable. What a concept.
Market Data 
Markets 
AI
